Anjali Mishra

Anjali Mishra

Auto-generated profile, based on publicly available information

Anjali Mishra

Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
PSPaola Sindaco
Paola Sindaco
HPHritisha Pandey
Hritisha Pandey
CIColleen Isabelle
Colleen Isabelle
NCNitin Chakravarti
Nitin Chakravarti
JBJonathan Brammer
Jonathan Brammer
AMAnjali Mishra
Anjali Mishra
Cytokines are a vital component of the immune system that controls the activation and growth of blood cells. However, chronic overexpression of cytokines can trigger cellular events leading to malignant transformation. The cytokine interleukin-15 (IL-15) is of particular interest, which has been shown to contribute to the development and progression of various hematological malignancies. This review will provide an overview of the impact of the immunopathogenic function of IL-15 by studying its role in cell survival, proliferation, inflammation, and treatment resistance. We will also review therapeutic approaches for inhibiting IL-15 in blood cancers.

4 March 2022 in Blood Cancer Discovery
Verified
Journal Article
Closed access
PDF file
BMBethany Mundy-Bosse
Bethany Mundy-Bosse
CWChristoph Weigel
Christoph Weigel
YWYue-Zhong Wu
Yue-Zhong Wu
SASalma Abdelbaky
Salma Abdelbaky
YYYoussef Youssef
Youssef Youssef
COChristopher C. Oakes
Christopher C. Oakes
Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive, rare lymphoma of natural killer (NK) cell origin with poor clinical outcomes. Here we used phenotypic and molecular profiling, including epigenetic analyses, to investigate how ENKTL ontogeny relates to normal NK-cell development. We demonstrate that neoplastic NK cells are stably, but reversibly, arrested at earlier stages of NK-cell maturation. Genes downregulated in the most epigenetic immature tumors were associated with polycomb silencing along with genomic gain and overexpression of EZH2. ENKTL cells exhibited genome-wide DNA hypermethylation. Tumor-specific DNA methylation gains were associated with polycomb-marked regions, involving extensive gene silencing and loss of transcription factor binding. To investigate therapeutic targeting, we treated novel patient-derived xenograft (PDX) models of ENKTL with the DNA hypomethylating agent, 5-azacytidine. Treatment led to reexpression of NK-cell developmental genes, phenotypic NK-cell differentiation, and prolongation of survival. These studies lay the foundation for epigenetic-directed therapy in ENKTL. Significance: Through epigenetic and transcriptomic analyses of ENKTL, a rare, aggressive malignancy, along with normal NK-cell developmental intermediates, we identified that extreme DNA hypermethylation targets genes required for NK-cell development. Disrupting this epigenetic blockade in novel PDX models led to ENKTL differentiation and improved survival. This article is highlighted in the In This Issue feature, p. 85

1 August 2021 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
EHEverardo Hegewisch-Solloa
Everardo Hegewisch-Solloa
SSSeungmae Seo
Seungmae Seo
BMBethany L. Mundy-Bosse
Bethany L. Mundy-Bosse
AMAnjali Mishra
Anjali Mishra
EWErik H. Waldman
Erik H. Waldman
EMEmily M. Mace
Emily M. Mace
NK cells are innate immune cells that reside within tissue and circulate in peripheral blood. They interact with a variety of microenvironments, yet how NK cells engage with these varied microenvironments is not well documented. The adhesome represents a molecular network of defined and predicted integrin-mediated signaling interactions. In this study, we define the integrin adhesome expression profile of NK cells from human tonsil, peripheral blood, and those derived from human hematopoietic precursors through stromal cell coculture systems. We report that the site of cell isolation and NK cell developmental stage dictate differences in expression of adhesome associated genes and proteins. Furthermore, we define differences in cortical actin content associated with differential expression of actin regulating proteins, suggesting that differences in adhesome expression are associated with differences in cortical actin homeostasis. These data provide understanding of the diversity of human NK cell populations and how they engage with their microenvironment.

1 September 2019 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
RKRebecca Kohnken
Rebecca Kohnken
BMBetina McNeil
Betina McNeil
JWJing Wen
Jing Wen
KMKathleen McConnell
Kathleen McConnell
LGLeah Grinshpun
Leah Grinshpun
AMAnjali Mishra
Anjali Mishra

12 October 2023 in Blood
Verified
Journal Article
Open access
PDF file
JBJonathan Brammer
Jonathan Brammer
KBKaren Ballen
Karen Ballen
LSLubomir Sokol
Lubomir Sokol
Christiane QuerfeldChristiane Querfeld
Christiane Querfeld
RNRyotaro Nakamura
Ryotaro Nakamura
TLThomas Loughran
Thomas Loughran
T-cell large granular lymphocytic leukemia (T-LGLL) is a clonal proliferation of cytotoxic T lymphocytes that can result in severe neutropenia, anemia, and bone marrow failure. Strong evidence from patients and mouse models demonstrate the critical role of interleukin-15 (IL-15) in T-LGLL pathogenesis. BNZ-1 is a pegylated peptide that selectively inhibits the binding of IL-15 and other γc cytokines to their cellular receptor complex, which has demonstrated efficacy in ex vivo T-LGLL cells and transgenic mice in preclinical studies. We conducted a phase 1/2 trial of BNZ-1 in patients with T-LGLL who had hematocytopenias (anemia or neutropenia) and required therapy. Clinical responses were assessed using hematologic parameters (improvement in hematocytopenias) based on response criteria from the Eastern Cooperative Oncology Group 5998 T-LGLL trial. BNZ-1 demonstrated clinical partial responses in 20% of patients with T-LGLL with minimal toxicity and the maximum tolerated dose was not reached. Furthermore, T-LGL leukemic cells showed significantly increased apoptosis in response to BNZ-1 treatment as early as day 2, including in clinical nonresponders, with changes that remained statistically different from baseline throughout treatment (P < .005). We report first-in-human proof that T-LGL leukemic cells are dependent on IL-15 and that intervention with IL-15 inhibition with BNZ-1 in patients with T-LGLL shows therapeutic effects, which carries important implications for the understanding of the pathogenesis of this disease. This trial was registered at www.clinicaltrials.gov as #NCT03239392.

10 March 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
CIColleen Isabelle
Colleen Isabelle
ABAmy Boles
Amy Boles
NCNitin Chakravarti
Nitin Chakravarti
PPPierluigi Porcu
Pierluigi Porcu
JBJonathan Brammer
Jonathan Brammer
AMAnjali Mishra
Anjali Mishra
Large granular lymphocytic leukemia (LGLL) is a lymphoproliferative disorder of older adults characterized by the clonal expansion of cytotoxic T/natural killer cells due to constitutive pro-survival signaling. In recent years, it has become clear that cytokines and their receptors are aberrantly expressed in LGLL cells. The exact initiation process of LGLL is unknown, although several cytokine-driven mechanisms have emerged. Elevated levels of several cytokines, including interleukin-15 (IL-15) and platelet-derived growth factor (PDGF), have been described in LGLL patients. Evidence from humans and animal models has shown that cytokines may also contribute to the co-occurrence of a wide range of autoimmune diseases seen in patients with LGLL. The goal of this review is to provide a comprehensive analysis of the link between cytokines and pro-survival signaling in LGLL and to discuss the various strategies and research approaches that are being utilized to study this link. This review will also highlight the importance of cytokine-targeted therapeutics in the treatment of LGLL.